

Clinical trials of bucindolol

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
bucindolol vs placebo			
Pollock , 1990 n=12/7 follow-up: 3 months	bucindolol target dose 100mg twice daily versus placebo	Patientst with stable, chronic heart failure with a dilated cardiomyopathy due to ischemic or isopathic causes	Parallel groups Double blind US
Woodley , 1991 n=29/29 follow-up: 3 mo	bucindolol versus placebo	NYHA 2-3, IDC/CAD	
MERIT-HF (elderly subgroup) , 1999 n=1330 follow-up:	Bucindolol versus placebo	Patients aged 65 years and olderwith chronic heart failure in NYHA functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy	
Bristow , 1994 n=105/34 follow-up: 3 mo	bucindolol versus placebo	NYHA 2-3, IDC	
BEST , 2001 [NCT00000560] n=1354/1354 follow-up: 2 years	bucindolol titrated to 50mg txice daily versus placebo	patients with heart failure NYHA class III or IV and a left ventricular ejection fraction of 35 percent or lower	Parallel groups Double blind US, Canada

More details and results :

- beta-blockers for heart failure in all type of heart failure at <http://www.trialresultscenter.org/go-Q44>
- beta-blockers for heart failure in elderly patients at <http://www.trialresultscenter.org/go-Q119>

References

Pollock, 1990:

Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML, Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990; 66:603-7 [[1975473](#)]

Woodley, 1991:

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, et al, Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 1991; 84:2426-41 [[1683602](#)]

Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, et al, Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. *Circulation* 1991; 84:2426-41 [[1683602](#)]

MERIT-HF (elderly subgroup), 1999:

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) *Lancet* 1999;353:2001-7 [[10376614](#)]

Bristow, 1994:

Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al, Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. *Circulation* 1994; 89:1632-42 [[7908610](#)]

BEST, 2001:

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. *N Engl J Med* 2001 May 31;344:1659-67 [[11386264](#)]

Entry terms: bucindolol, bucindolol hydrochloride, MJ 13105,